Treatment with intravenous immunoglobulins and methylprednisolone may significantly decrease loss of renal function in chronic-active antibody-mediated rejection

BACKGROUND: Chronic-active antibody mediated rejection (c-aABMR) is a major contributor to long-term kidney allograft loss. We conducted a retrospective analysis to establish the efficacy of treatment with intravenous immunoglobulins (IVIG) and pulse methylprednisolone (MP) of patients with c-aABMR....

Descripción completa

Detalles Bibliográficos
Autores principales: Sablik, Kasia A., Clahsen-van Groningen, Marian C., Looman, Caspar W. N., Damman, Jeffrey, van Agteren, Madelon, Betjes, Michiel G. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6567552/
https://www.ncbi.nlm.nih.gov/pubmed/31200654
http://dx.doi.org/10.1186/s12882-019-1385-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6567552/
https://www.ncbi.nlm.nih.gov/pubmed/31200654
http://dx.doi.org/10.1186/s12882-019-1385-z

Ejemplares similares